Provided by Tiger Trade Technology Pte. Ltd.

Harpoon Therapeutics Inc.

23.01
0.0000
Volume:- -
Turnover:151.96M
Market Cap:492.35M
PE:-2.79
High:23.01
Open:23.01
Low:23.01
Close:23.01
52wk High:23.21
52wk Low:3.11
Shares:21.40M
Float Shares:10.43M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.2467
EPS(LYR):-20.4209
ROE:-284.32%
ROA:-35.66%
PB:108.42
PE(LYR):-1.13

Loading ...

Company Profile

Company Name:
Harpoon Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California.